A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Last updated:
2026-08-01
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ABT-494 TO PLACEBO AND TO ADALIMUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO ARE ON A STABLE BACKGROUND OF METHOTREXATE (MTX) AND WHO HAVE AN INADEQUATE RESPONSE TO MTX (MTX-IR)

Intervention/treatment:
UPADACITINIB (ABT-494)
Medical condition:
RHEUMATOID ARTHRITIS
Protocol code:
M14-465
Control number:
188666
Status:
Active, not recruiting
Approved:
November 19, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02629159
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

Manitoba

Ciads /Id# 142880
Winnipeg, Manitoba, R3N 0K6
Manitoba Clinic /ID# 161434
Winnipeg, Manitoba, R3A IM3

Newfoundland and Labrador

St. Clare's Mercy Hospital /ID# 142879
St. John's, Newfoundland and Labrador, A1C 5B8

Ontario

Adachi Medicine Prof. Corp /ID# 154205
Hamilton, Ontario, L8N 1Y2
CA Ctr for Clin Trials CCCT /ID# 157379
Thornhill, Ontario, L4J 1W3

Quebec

Groupe de Recherche en Maladies Osseuses /ID# 142878
Sainte-Foy, Quebec, G1V 3M7

Results

See the results from the trial NCT02629159. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?